> Details

Vila-Sanjuán, Sofía; Nuñez-Gil, Ivan Javier; Vedia, Oscar; Corbi-Pascual, Miguel; Salamanca, Jorge; Martinez-Selles, Manuel; Blanco, Emilia; Almendro-Delia, Manuel; Pérez-Castellanos, Alberto; Martin-Garcia, Agustin C; Tomasino, Marco; Vazirani, Ravi; Fernández-Cordón, Clara; Duran Cambra, Albert; Becerra-Muñoz, Víctor Manuel; Guillén, Marta; Reyes, Juan Albistur; Uribarri, Aitor

Left ventricular outflow tract obstruction in Takotsubo syndrome with cardiogenic shock: prognosis and treatment

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Left ventricular outflow tract obstruction in Takotsubo syndrome with cardiogenic shock: prognosis and treatment
  • Contributor: Vila-Sanjuán, Sofía; Nuñez-Gil, Ivan Javier; Vedia, Oscar; Corbi-Pascual, Miguel; Salamanca, Jorge; Martinez-Selles, Manuel; Blanco, Emilia; Almendro-Delia, Manuel; Pérez-Castellanos, Alberto; Martin-Garcia, Agustin C; Tomasino, Marco; Vazirani, Ravi; Fernández-Cordón, Clara; Duran Cambra, Albert; Becerra-Muñoz, Víctor Manuel; Guillén, Marta; Reyes, Juan Albistur; Uribarri, Aitor
  • Published: BMJ, 2024
  • Published in: Heart (2024), Seite heartjnl-2024-324205
  • Language: English
  • DOI: 10.1136/heartjnl-2024-324205
  • ISSN: 1355-6037; 1468-201X
  • Origination:
  • Footnote:
  • Description: BackgroundPatients with Takotsubo syndrome (TTS) who develop cardiogenic shock may present with left ventricular outflow tract obstruction (LVOTO). The prognosis and treatment of this population have not been defined in previous studies. The aim of this study is to describe the clinical presentation, management, evolution and prognosis of a subgroup of patients with TTS and cardiogenic shock according to whether they present with LVOTO or not.MethodsWe analysed patients with TTS recruited from 2003 to 2022 in a multicentre registry. Patients were selected if they presented cardiogenic shock during their admission. This analysis was compared according to the presence or absence of LVOTO.Results322 patients were included, 58 (18%) of whom had LVOTO. The majority were treated with vasoactive and inotropic therapy (VIT) and its use was strongly associated with having LVOTO (77.6% vs 57.6%, p<0.001). Only five (3.3%) patients without LVOTO and two (4.4%) in the LVOTO group treated with VIT developed or worsened the obstruction. Furthermore, patients with LVOTO presented higher in-hospital complications including ventricular arrhythmias (15.5% vs 8.7%, p=0.017), major bleeding (13.8% vs 6.1%, p=0.042) and acute kidney failure (48.3% vs 28.4%, p=0.003). However, at both 90 days and 5 years, the cumulative incidence of all-cause death was not significantly different between the patients with and without LVOTO (HR 1.20, 95% CI 0.60 to 2.40 for 90 days, and HR 1.69, 95% CI 0.89 to 3.21 for 5 years).ConclusionsLVOTO is not uncommon in patients with TTS and cardiogenic shock. It is associated with a more aggressive in-hospital course and our data is unable to rule out an association between the presence of LVOTO and long-term prognosis of patients with TTS. The development or worsening of LVOTO directly related to inotropic or vasoactive support was low.